Karyopharm Therapeutics Inc. (KPTI) 10-Year Financial Performance & Capital Metrics

KPTI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Show more

Revenue $145M -0.5%
EBITDA -$119M +7.7%
Net Income -$76M +46.6%
EPS (Diluted) -9.41 +49.9%
Gross Margin 95.86% -0.8%
EBITDA Margin -82.01% +7.2%
Operating Margin -82.24% +7.3%
Net Margin -52.62% +46.3%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.19 +41.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 28.9%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y90.64%

5Y28.85%

3Y-11.54%

TTM-3.98%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-42.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.94%

ROCE

10Y Avg-67.97%

5Y Avg-63.52%

3Y Avg-69.49%

Latest-98.26%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.8B	105.95	706.33	14.76%	24.69%	25.55%	1.2%	0.01
TGTXTG Therapeutics, Inc.	4.69B	29.54	196.93	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.68B	28.73	2.47	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.9M	3.75	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	20.96M	1.02	-0.40	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	323.62M	14.77	-0.43			-94.52%		0.33
FATEFate Therapeutics, Inc.	124.58M	1.08	-0.66	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	131.65M	7.19	-0.76	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	250K	154K	1.6M	30.34M	40.89M	108.08M	209.82M	157.07M	146.03M	145.24M
Revenue Growth %	0.09%	-0.38%	9.42%	17.9%	0.35%	1.64%	0.94%	-0.25%	-0.07%	-0.01%
Cost of Goods Sold+	97.74M	86.94M	107.27M	161.37M	2.41M	2.71M	3.4M	5.21M	4.94M	6.01M
COGS % of Revenue	390.98%	564.53%	66.84%	5.32%	0.06%	0.03%	0.02%	0.03%	0.03%	0.04%
Gross Profit+	-97.49M	-86.78M	-105.67M	-131.04M	38.49M	105.38M	206.42M	151.86M	141.09M	139.23M
Gross Margin %	-389.98%	-563.53%	-65.84%	-4.32%	0.94%	0.97%	0.98%	0.97%	0.97%	0.96%
Gross Profit Growth %	-0.63%	0.11%	-0.22%	-0.24%	1.29%	1.74%	0.96%	-0.26%	-0.07%	-0.01%
Operating Expenses+	119.33M	110.89M	132.14M	210.22M	227.76M	277.23M	304.69M	294.06M	270.63M	258.67M
OpEx % of Revenue	477.3%	720.04%	82.33%	6.93%	5.57%	2.56%	1.45%	1.87%	1.85%	1.78%
Selling, General & Admin	21.58M	23.95M	24.87M	48.85M	105.42M	126.42M	143.85M	145.4M	131.88M	115.44M
SG&A % of Revenue	86.33%	155.51%	15.5%	1.61%	2.58%	1.17%	0.69%	0.93%	0.9%	0.79%
Research & Development	97.74M	86.94M	107.27M	161.37M	122.34M	150.81M	160.84M	148.66M	138.75M	143.23M
R&D % of Revenue	390.98%	564.53%	66.84%	5.32%	2.99%	1.4%	0.77%	0.95%	0.95%	0.99%
Other Operating Expenses	-2K	10K	-81K	-33K	0	0	0	0	0	0
Operating Income+	-119.08M	-110.73M	-130.54M	-179.88M	-189.28M	-171.85M	-98.27M	-142.2M	-129.54M	-119.44M
Operating Margin %	-476.3%	-719.04%	-81.33%	-5.93%	-4.63%	-1.59%	-0.47%	-0.91%	-0.89%	-0.82%
Operating Income Growth %	-0.57%	0.07%	-0.18%	-0.38%	-0.05%	0.09%	0.43%	-0.45%	0.09%	0.08%
EBITDA+	-118.44M	-110.02M	-129.82M	-179.15M	-188.3M	-170.88M	-97.48M	-141.58M	-129.01M	-119.1M
EBITDA Margin %	-473.77%	-714.38%	-80.89%	-5.91%	-4.6%	-1.58%	-0.46%	-0.9%	-0.88%	-0.82%
EBITDA Growth %	-0.57%	0.07%	-0.18%	-0.38%	-0.05%	0.09%	0.43%	-0.45%	0.09%	0.08%
D&A (Non-Cash Add-back)	634K	717K	713K	735K	974K	972K	789K	621K	530K	340K
EBIT	-119.08M	-109.44M	-128.92M	-175.89M	-183.9M	-168.82M	-97.77M	-139.93M	-118.95M	-38.94M
Net Interest Income+	897K	1.28M	1.7M	1.53M	-10.22M	-24.32M	-25.46M	-22.64M	-12.88M	-30.02M
Interest Income	897K	1.28M	1.7M	4.03M	5.42M	2.82M	582K	2.36M	10.94M	7.4M
Interest Expense	0	0	0	2.49M	15.65M	27.14M	26.05M	25M	23.82M	37.42M
Other Income/Expense	895K	1.29M	1.62M	1.5M	-10.28M	-24.11M	-25.55M	-22.72M	-13.24M	43.08M
Pretax Income+	-118.18M	-109.44M	-128.92M	-178.38M	-199.55M	-195.96M	-123.82M	-164.92M	-142.78M	-76.36M
Pretax Margin %	-472.72%	-710.64%	-80.32%	-5.88%	-4.88%	-1.81%	-0.59%	-1.05%	-0.98%	-0.53%
Income Tax+	-895K	139K	63K	26K	40K	309K	268K	369K	323K	57K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Net Margin %	-472.72%	-711.54%	-80.36%	-5.88%	-4.88%	-1.82%	-0.59%	-1.05%	-0.98%	-0.53%
Net Income Growth %	-0.56%	0.07%	-0.18%	-0.38%	-0.12%	0.02%	0.37%	-0.33%	0.13%	0.47%
Net Income (Continuing)	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-49.80	-43.80	-42.15	-47.11	-48.32	-40.87	-24.75	-30.28	-18.79	-9.41
EPS Growth %	-0.37%	0.12%	0.04%	-0.12%	-0.03%	0.15%	0.39%	-0.22%	0.38%	0.5%
EPS (Basic)	-49.80	-43.80	-42.15	-47.11	-48.32	-40.87	-24.75	-30.28	-18.79	-9.41
Diluted Shares Outstanding	2.37M	2.5M	3.06M	3.79M	4.13M	4.8M	5.01M	5.46M	7.61M	8.12M
Basic Shares Outstanding	2.37M	2.5M	3.06M	3.79M	4.13M	4.8M	5.01M	5.46M	7.61M	8.12M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	177.6M	131.64M	148.42M	334.61M	278.57M	276.53M	275.61M	350.16M	233.92M	156.49M
Cash & Short-Term Investments	175.63M	129.55M	146.47M	328.2M	261.96M	249.24M	228.62M	277.97M	191.44M	108.71M
Cash Only	58.36M	49.66M	69M	118.02M	128.86M	85.92M	190.46M	135.19M	52.23M	62.48M
Short-Term Investments	117.28M	79.89M	77.47M	210.18M	133.1M	163.32M	38.16M	142.78M	139.21M	46.24M
Accounts Receivable	0	0	0	0	7.86M	12.88M	22.5M	47.09M	26.96M	30.77M
Days Sales Outstanding	-	-	-	-	70.17	43.5	39.14	109.42	67.39	77.32
Inventory	0	0	0	0	346K	2.64M	4.11M	4.22M	3.04M	4.74M
Days Inventory Outstanding	-	-	-	-	52.47	356.77	440.53	295.75	224.75	287.95
Other Current Assets	0	0	200K	0	1.12M	2.48M	6.35M	20.89M	12.47M	12.28M
Total Non-Current Assets+	37.84M	48.75M	31.87M	6.58M	16.39M	36.52M	29.7M	8.01M	6.52M	7.93M
Property, Plant & Equipment	3.48M	2.84M	2.19M	3.86M	13.66M	11.58M	9.56M	7.38M	4.88M	6.28M
Fixed Asset Turnover	0.07x	0.05x	0.73x	7.85x	2.99x	9.33x	21.95x	21.29x	29.91x	23.11x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	33.88M	45.43M	29.4M	2M	2.02M	24.21M	0	0	0	0
Other Non-Current Assets	482K	479K	290K	716K	714K	722K	20.14M	633K	1.64M	1.64M
Total Assets+	215.44M	180.38M	180.29M	341.19M	294.96M	313.05M	305.31M	358.17M	240.44M	164.42M
Asset Turnover	0.00x	0.00x	0.01x	0.09x	0.14x	0.35x	0.69x	0.44x	0.61x	0.88x
Asset Growth %	-0.02%	-0.16%	-0%	0.89%	-0.14%	0.06%	-0.02%	0.17%	-0.33%	-0.32%
Total Current Liabilities+	15.13M	16.48M	49.47M	46.9M	46.35M	60.2M	73.72M	65.91M	69.48M	92.26M
Accounts Payable	3.81M	4.75M	5.67M	4.33M	985K	4.45M	1.6M	2.77M	3.12M	5.11M
Days Payables Outstanding	14.22	19.95	19.28	9.8	149.37	600.46	171.99	194.16	230.65	310.31
Short-Term Debt	0	0	0	0	0	0	0	0	0	24.43M
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	297K	0	0	0	0
Other Current Liabilities	301K	363K	436K	717K	500K	609K	20.36M	21.47M	18.16M	15.56M
Current Ratio	11.74x	7.99x	3.00x	7.13x	6.01x	4.59x	3.74x	5.31x	3.37x	1.70x
Quick Ratio	11.74x	7.99x	3.00x	7.13x	6.00x	4.55x	3.68x	5.25x	3.32x	1.64x
Cash Conversion Cycle	-	-	-	-	-26.72	-200.19	307.68	211.01	61.48	54.96
Total Non-Current Liabilities+	1.95M	1.67M	1.36M	111.12M	198.84M	202.3M	311.26M	308.92M	307.17M	258.17M
Long-Term Debt	0	0	0	102.66M	109.86M	117.93M	169.29M	170.1M	170.92M	162.95M
Capital Lease Obligations	0	0	0	0	13.2M	11.29M	8.97M	6.1M	2.79M	6.71M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.95M	1.67M	1.36M	3.92M	73.59M	73.09M	133M	132.72M	133.46M	88.51M
Total Liabilities	17.08M	18.14M	50.83M	158.02M	245.19M	262.5M	384.98M	374.83M	376.64M	350.44M
Total Debt+	0	0	0	102.66M	124.7M	131.13M	180.58M	179.07M	177.02M	194.52M
Net Debt	-58.36M	-49.66M	-69M	-15.36M	-4.15M	45.21M	-9.88M	43.89M	124.78M	132.05M
Debt / Equity	-	-	-	0.56x	2.51x	2.59x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-72.16x	-12.10x	-6.33x	-3.77x	-5.69x	-5.44x	-3.19x
Total Equity+	198.37M	162.24M	129.46M	183.17M	49.77M	50.55M	-79.67M	-16.66M	-136.21M	-186.02M
Equity Growth %	-0.04%	-0.18%	-0.2%	0.41%	-0.73%	0.02%	-2.58%	0.79%	-7.18%	-0.37%
Book Value per Share	83.54	64.86	42.31	48.37	12.05	10.52	-15.89	-3.05	-17.89	-22.90
Total Shareholders' Equity	198.37M	162.24M	129.46M	183.17M	49.77M	50.55M	-79.67M	-16.66M	-136.21M	-186.02M
Common Stock	4K	4K	5K	6K	7K	7K	8K	12K	12K	13K
Retained Earnings	-256.53M	-366.1M	-495.34M	-673.75M	-873.34M	-1.07B	-1.18B	-1.34B	-1.49B	-1.56B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-282K	-274K	-217K	-244K	-37K	518K	191K	-638K	-161K	-356K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-94.03M	-84.39M	-73.72M	-159.12M	-190.82M	-160.23M	-107.12M	-149.55M	-92.72M	-127.49M
Operating CF Margin %	-376.12%	-547.99%	-45.93%	-5.25%	-4.67%	-1.48%	-0.51%	-0.95%	-0.63%	-0.88%
Operating CF Growth %	-0.83%	0.1%	0.13%	-1.16%	-0.2%	0.16%	0.33%	-0.4%	0.38%	-0.37%
Net Income	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Depreciation & Amortization	634K	717K	713K	735K	974K	972K	789K	621K	530K	340K
Stock-Based Compensation	17.06M	22.28M	20.41M	17.27M	15.29M	24.41M	29.78M	35.4M	21.71M	18.43M
Deferred Taxes	1.78M	0	0	29K	-1.38M	904K	1.45M	0	0	0
Other Non-Cash Items	685K	1.2M	1.19M	1.42M	7.19M	8.4M	8.13M	-294K	-3.28M	-69.53M
Working Capital Changes	4M	987K	32.96M	-169K	-13.31M	1.36M	-23.19M	-19.99M	31.41M	-302K
Change in Receivables	0	0	0	0	-7.86M	-5.02M	-9.62M	-5.08M	20.12M	-3.8M
Change in Inventory	0	0	0	0	-346K	-2.63M	-1.46M	-118K	1.18M	-1.7M
Change in Payables	-2.43M	945K	909K	-1.38M	-3.3M	3.46M	-2.85M	1.17M	350K	1.98M
Cash from Investing+	-90.82M	24.59M	17.11M	-107.66M	78.45M	-53.69M	141.84M	-104.26M	7.94M	95.47M
Capital Expenditures	-1.42M	-70K	-62K	-2.36M	-206K	-145K	-5.71M	-118K	0	-142K
CapEx % of Revenue	5.66%	0.45%	0.04%	0.08%	0.01%	0%	0.03%	0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-82K	24.66M	17.17M	-105.3M	78.66M	-53.54M	-5.5M	-104.26M	0	0
Cash from Financing+	92.7M	51.16M	75.74M	316.11M	124.31M	172.08M	73.65M	193.74M	1.12M	41.65M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	616K	591K	858K	3.52M	78.11M	10.31M	3.75M	3.98M	0	-43.11M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-95.44M	-84.46M	-73.78M	-161.48M	-191.03M	-160.38M	-112.83M	-149.67M	-92.72M	-127.63M
FCF Margin %	-381.78%	-548.45%	-45.97%	-5.32%	-4.67%	-1.48%	-0.54%	-0.95%	-0.63%	-0.88%
FCF Growth %	-0.76%	0.12%	0.13%	-1.19%	-0.18%	0.16%	0.3%	-0.33%	0.38%	-0.38%
FCF per Share	-40.19	-33.76	-24.11	-42.64	-46.25	-33.39	-22.50	-27.42	-12.18	-15.71
FCF Conversion (FCF/Net Income)	0.80x	0.77x	0.57x	0.89x	0.96x	0.82x	0.86x	0.90x	0.65x	1.67x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.34%	-60.77%	-88.43%	-114.13%	-171.36%	-391.29%	-	-	-	-
Return on Invested Capital (ROIC)	-91.04%	-65.76%	-113.15%	-118.2%	-133.02%	-182.33%	-2375.99%	-391.67%	-1229.11%	-
Gross Margin	-38997.6%	-56353.25%	-6583.68%	-431.95%	94.11%	97.5%	98.38%	96.68%	96.62%	95.86%
Net Margin	-47272.4%	-71153.9%	-8036.39%	-588.1%	-488.08%	-181.59%	-59.14%	-105.23%	-97.99%	-52.62%
Debt / Equity	-	-	-	0.56x	2.51x	2.59x	-	-	-	-
Interest Coverage	-	-	-	-72.16x	-12.10x	-6.33x	-3.77x	-5.69x	-5.44x	-3.19x
FCF Conversion	0.80x	0.77x	0.57x	0.89x	0.96x	0.82x	0.86x	0.90x	0.65x	1.67x
Revenue Growth	9.17%	-38.4%	942.21%	1790.09%	34.8%	164.31%	94.12%	-25.14%	-7.03%	-0.55%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	15.67M	24.36M	28.01M
License and Service Growth	-	-	-	-	55.44%	15.00%
Health Care, Other	-	-	-	-	-	2.74M
Health Care, Other Growth	-	-	-	-	-	-
License	-	-	-	-	3.5M	-
License Growth	-	-	-	-	-	-
Royalty	-	-	-	300K	1.5M	-
Royalty Growth	-	-	-	-	400.00%	-
License And Other	10.35M	31.88M	111.38M	-	-	-
License And Other Growth	-	207.88%	249.44%	-	-	-
Product	30.54M	76.21M	98.44M	-	-	-
Product Growth	-	149.54%	29.16%	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
CANADA	-	5M	-	-	-	-
CANADA Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Karyopharm Therapeutics Inc. (KPTI) reported $142.5M in revenue for fiscal year 2024. This represents a 93670% increase from $0.2M in 2011.

Karyopharm Therapeutics Inc. (KPTI) saw revenue decline by 0.5% over the past year.

Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $124.6M for fiscal year 2024.

Dividend & Returns

Karyopharm Therapeutics Inc. (KPTI) had negative free cash flow of $83.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Karyopharm Therapeutics Inc. (KPTI) 10-Year Financial Performance & Capital Metrics

KPTI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $145M -0.5%
EBITDA -$119M +7.7%
Net Income -$76M +46.6%
EPS (Diluted) -9.41 +49.9%
Gross Margin 95.86% -0.8%
EBITDA Margin -82.01% +7.2%
Operating Margin -82.24% +7.3%
Net Margin -52.62% +46.3%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.19 +41.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 28.9%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y90.64%

5Y28.85%

3Y-11.54%

TTM-3.98%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-42.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM14.94%

ROCE

10Y Avg-67.97%

5Y Avg-63.52%

3Y Avg-69.49%

Latest-98.26%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.8B	105.95	706.33	14.76%	24.69%	25.55%	1.2%	0.01
TGTXTG Therapeutics, Inc.	4.69B	29.54	196.93	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.68B	28.73	2.47	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.9M	3.75	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	20.96M	1.02	-0.40	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	323.62M	14.77	-0.43			-94.52%		0.33
FATEFate Therapeutics, Inc.	124.58M	1.08	-0.66	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	131.65M	7.19	-0.76	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	250K	154K	1.6M	30.34M	40.89M	108.08M	209.82M	157.07M	146.03M	145.24M
Revenue Growth %	0.09%	-0.38%	9.42%	17.9%	0.35%	1.64%	0.94%	-0.25%	-0.07%	-0.01%
Cost of Goods Sold+	97.74M	86.94M	107.27M	161.37M	2.41M	2.71M	3.4M	5.21M	4.94M	6.01M
COGS % of Revenue	390.98%	564.53%	66.84%	5.32%	0.06%	0.03%	0.02%	0.03%	0.03%	0.04%
Gross Profit+	-97.49M	-86.78M	-105.67M	-131.04M	38.49M	105.38M	206.42M	151.86M	141.09M	139.23M
Gross Margin %	-389.98%	-563.53%	-65.84%	-4.32%	0.94%	0.97%	0.98%	0.97%	0.97%	0.96%
Gross Profit Growth %	-0.63%	0.11%	-0.22%	-0.24%	1.29%	1.74%	0.96%	-0.26%	-0.07%	-0.01%
Operating Expenses+	119.33M	110.89M	132.14M	210.22M	227.76M	277.23M	304.69M	294.06M	270.63M	258.67M
OpEx % of Revenue	477.3%	720.04%	82.33%	6.93%	5.57%	2.56%	1.45%	1.87%	1.85%	1.78%
Selling, General & Admin	21.58M	23.95M	24.87M	48.85M	105.42M	126.42M	143.85M	145.4M	131.88M	115.44M
SG&A % of Revenue	86.33%	155.51%	15.5%	1.61%	2.58%	1.17%	0.69%	0.93%	0.9%	0.79%
Research & Development	97.74M	86.94M	107.27M	161.37M	122.34M	150.81M	160.84M	148.66M	138.75M	143.23M
R&D % of Revenue	390.98%	564.53%	66.84%	5.32%	2.99%	1.4%	0.77%	0.95%	0.95%	0.99%
Other Operating Expenses	-2K	10K	-81K	-33K	0	0	0	0	0	0
Operating Income+	-119.08M	-110.73M	-130.54M	-179.88M	-189.28M	-171.85M	-98.27M	-142.2M	-129.54M	-119.44M
Operating Margin %	-476.3%	-719.04%	-81.33%	-5.93%	-4.63%	-1.59%	-0.47%	-0.91%	-0.89%	-0.82%
Operating Income Growth %	-0.57%	0.07%	-0.18%	-0.38%	-0.05%	0.09%	0.43%	-0.45%	0.09%	0.08%
EBITDA+	-118.44M	-110.02M	-129.82M	-179.15M	-188.3M	-170.88M	-97.48M	-141.58M	-129.01M	-119.1M
EBITDA Margin %	-473.77%	-714.38%	-80.89%	-5.91%	-4.6%	-1.58%	-0.46%	-0.9%	-0.88%	-0.82%
EBITDA Growth %	-0.57%	0.07%	-0.18%	-0.38%	-0.05%	0.09%	0.43%	-0.45%	0.09%	0.08%
D&A (Non-Cash Add-back)	634K	717K	713K	735K	974K	972K	789K	621K	530K	340K
EBIT	-119.08M	-109.44M	-128.92M	-175.89M	-183.9M	-168.82M	-97.77M	-139.93M	-118.95M	-38.94M
Net Interest Income+	897K	1.28M	1.7M	1.53M	-10.22M	-24.32M	-25.46M	-22.64M	-12.88M	-30.02M
Interest Income	897K	1.28M	1.7M	4.03M	5.42M	2.82M	582K	2.36M	10.94M	7.4M
Interest Expense	0	0	0	2.49M	15.65M	27.14M	26.05M	25M	23.82M	37.42M
Other Income/Expense	895K	1.29M	1.62M	1.5M	-10.28M	-24.11M	-25.55M	-22.72M	-13.24M	43.08M
Pretax Income+	-118.18M	-109.44M	-128.92M	-178.38M	-199.55M	-195.96M	-123.82M	-164.92M	-142.78M	-76.36M
Pretax Margin %	-472.72%	-710.64%	-80.32%	-5.88%	-4.88%	-1.81%	-0.59%	-1.05%	-0.98%	-0.53%
Income Tax+	-895K	139K	63K	26K	40K	309K	268K	369K	323K	57K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Net Margin %	-472.72%	-711.54%	-80.36%	-5.88%	-4.88%	-1.82%	-0.59%	-1.05%	-0.98%	-0.53%
Net Income Growth %	-0.56%	0.07%	-0.18%	-0.38%	-0.12%	0.02%	0.37%	-0.33%	0.13%	0.47%
Net Income (Continuing)	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-49.80	-43.80	-42.15	-47.11	-48.32	-40.87	-24.75	-30.28	-18.79	-9.41
EPS Growth %	-0.37%	0.12%	0.04%	-0.12%	-0.03%	0.15%	0.39%	-0.22%	0.38%	0.5%
EPS (Basic)	-49.80	-43.80	-42.15	-47.11	-48.32	-40.87	-24.75	-30.28	-18.79	-9.41
Diluted Shares Outstanding	2.37M	2.5M	3.06M	3.79M	4.13M	4.8M	5.01M	5.46M	7.61M	8.12M
Basic Shares Outstanding	2.37M	2.5M	3.06M	3.79M	4.13M	4.8M	5.01M	5.46M	7.61M	8.12M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	177.6M	131.64M	148.42M	334.61M	278.57M	276.53M	275.61M	350.16M	233.92M	156.49M
Cash & Short-Term Investments	175.63M	129.55M	146.47M	328.2M	261.96M	249.24M	228.62M	277.97M	191.44M	108.71M
Cash Only	58.36M	49.66M	69M	118.02M	128.86M	85.92M	190.46M	135.19M	52.23M	62.48M
Short-Term Investments	117.28M	79.89M	77.47M	210.18M	133.1M	163.32M	38.16M	142.78M	139.21M	46.24M
Accounts Receivable	0	0	0	0	7.86M	12.88M	22.5M	47.09M	26.96M	30.77M
Days Sales Outstanding	-	-	-	-	70.17	43.5	39.14	109.42	67.39	77.32
Inventory	0	0	0	0	346K	2.64M	4.11M	4.22M	3.04M	4.74M
Days Inventory Outstanding	-	-	-	-	52.47	356.77	440.53	295.75	224.75	287.95
Other Current Assets	0	0	200K	0	1.12M	2.48M	6.35M	20.89M	12.47M	12.28M
Total Non-Current Assets+	37.84M	48.75M	31.87M	6.58M	16.39M	36.52M	29.7M	8.01M	6.52M	7.93M
Property, Plant & Equipment	3.48M	2.84M	2.19M	3.86M	13.66M	11.58M	9.56M	7.38M	4.88M	6.28M
Fixed Asset Turnover	0.07x	0.05x	0.73x	7.85x	2.99x	9.33x	21.95x	21.29x	29.91x	23.11x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	33.88M	45.43M	29.4M	2M	2.02M	24.21M	0	0	0	0
Other Non-Current Assets	482K	479K	290K	716K	714K	722K	20.14M	633K	1.64M	1.64M
Total Assets+	215.44M	180.38M	180.29M	341.19M	294.96M	313.05M	305.31M	358.17M	240.44M	164.42M
Asset Turnover	0.00x	0.00x	0.01x	0.09x	0.14x	0.35x	0.69x	0.44x	0.61x	0.88x
Asset Growth %	-0.02%	-0.16%	-0%	0.89%	-0.14%	0.06%	-0.02%	0.17%	-0.33%	-0.32%
Total Current Liabilities+	15.13M	16.48M	49.47M	46.9M	46.35M	60.2M	73.72M	65.91M	69.48M	92.26M
Accounts Payable	3.81M	4.75M	5.67M	4.33M	985K	4.45M	1.6M	2.77M	3.12M	5.11M
Days Payables Outstanding	14.22	19.95	19.28	9.8	149.37	600.46	171.99	194.16	230.65	310.31
Short-Term Debt	0	0	0	0	0	0	0	0	0	24.43M
Deferred Revenue (Current)	0	0	1000K	1000K	1000K	297K	0	0	0	0
Other Current Liabilities	301K	363K	436K	717K	500K	609K	20.36M	21.47M	18.16M	15.56M
Current Ratio	11.74x	7.99x	3.00x	7.13x	6.01x	4.59x	3.74x	5.31x	3.37x	1.70x
Quick Ratio	11.74x	7.99x	3.00x	7.13x	6.00x	4.55x	3.68x	5.25x	3.32x	1.64x
Cash Conversion Cycle	-	-	-	-	-26.72	-200.19	307.68	211.01	61.48	54.96
Total Non-Current Liabilities+	1.95M	1.67M	1.36M	111.12M	198.84M	202.3M	311.26M	308.92M	307.17M	258.17M
Long-Term Debt	0	0	0	102.66M	109.86M	117.93M	169.29M	170.1M	170.92M	162.95M
Capital Lease Obligations	0	0	0	0	13.2M	11.29M	8.97M	6.1M	2.79M	6.71M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.95M	1.67M	1.36M	3.92M	73.59M	73.09M	133M	132.72M	133.46M	88.51M
Total Liabilities	17.08M	18.14M	50.83M	158.02M	245.19M	262.5M	384.98M	374.83M	376.64M	350.44M
Total Debt+	0	0	0	102.66M	124.7M	131.13M	180.58M	179.07M	177.02M	194.52M
Net Debt	-58.36M	-49.66M	-69M	-15.36M	-4.15M	45.21M	-9.88M	43.89M	124.78M	132.05M
Debt / Equity	-	-	-	0.56x	2.51x	2.59x	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-72.16x	-12.10x	-6.33x	-3.77x	-5.69x	-5.44x	-3.19x
Total Equity+	198.37M	162.24M	129.46M	183.17M	49.77M	50.55M	-79.67M	-16.66M	-136.21M	-186.02M
Equity Growth %	-0.04%	-0.18%	-0.2%	0.41%	-0.73%	0.02%	-2.58%	0.79%	-7.18%	-0.37%
Book Value per Share	83.54	64.86	42.31	48.37	12.05	10.52	-15.89	-3.05	-17.89	-22.90
Total Shareholders' Equity	198.37M	162.24M	129.46M	183.17M	49.77M	50.55M	-79.67M	-16.66M	-136.21M	-186.02M
Common Stock	4K	4K	5K	6K	7K	7K	8K	12K	12K	13K
Retained Earnings	-256.53M	-366.1M	-495.34M	-673.75M	-873.34M	-1.07B	-1.18B	-1.34B	-1.49B	-1.56B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-282K	-274K	-217K	-244K	-37K	518K	191K	-638K	-161K	-356K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-94.03M	-84.39M	-73.72M	-159.12M	-190.82M	-160.23M	-107.12M	-149.55M	-92.72M	-127.49M
Operating CF Margin %	-376.12%	-547.99%	-45.93%	-5.25%	-4.67%	-1.48%	-0.51%	-0.95%	-0.63%	-0.88%
Operating CF Growth %	-0.83%	0.1%	0.13%	-1.16%	-0.2%	0.16%	0.33%	-0.4%	0.38%	-0.37%
Net Income	-118.18M	-109.58M	-128.98M	-178.41M	-199.59M	-196.27M	-124.09M	-165.29M	-143.1M	-76.42M
Depreciation & Amortization	634K	717K	713K	735K	974K	972K	789K	621K	530K	340K
Stock-Based Compensation	17.06M	22.28M	20.41M	17.27M	15.29M	24.41M	29.78M	35.4M	21.71M	18.43M
Deferred Taxes	1.78M	0	0	29K	-1.38M	904K	1.45M	0	0	0
Other Non-Cash Items	685K	1.2M	1.19M	1.42M	7.19M	8.4M	8.13M	-294K	-3.28M	-69.53M
Working Capital Changes	4M	987K	32.96M	-169K	-13.31M	1.36M	-23.19M	-19.99M	31.41M	-302K
Change in Receivables	0	0	0	0	-7.86M	-5.02M	-9.62M	-5.08M	20.12M	-3.8M
Change in Inventory	0	0	0	0	-346K	-2.63M	-1.46M	-118K	1.18M	-1.7M
Change in Payables	-2.43M	945K	909K	-1.38M	-3.3M	3.46M	-2.85M	1.17M	350K	1.98M
Cash from Investing+	-90.82M	24.59M	17.11M	-107.66M	78.45M	-53.69M	141.84M	-104.26M	7.94M	95.47M
Capital Expenditures	-1.42M	-70K	-62K	-2.36M	-206K	-145K	-5.71M	-118K	0	-142K
CapEx % of Revenue	5.66%	0.45%	0.04%	0.08%	0.01%	0%	0.03%	0%	-	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-82K	24.66M	17.17M	-105.3M	78.66M	-53.54M	-5.5M	-104.26M	0	0
Cash from Financing+	92.7M	51.16M	75.74M	316.11M	124.31M	172.08M	73.65M	193.74M	1.12M	41.65M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	616K	591K	858K	3.52M	78.11M	10.31M	3.75M	3.98M	0	-43.11M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-95.44M	-84.46M	-73.78M	-161.48M	-191.03M	-160.38M	-112.83M	-149.67M	-92.72M	-127.63M
FCF Margin %	-381.78%	-548.45%	-45.97%	-5.32%	-4.67%	-1.48%	-0.54%	-0.95%	-0.63%	-0.88%
FCF Growth %	-0.76%	0.12%	0.13%	-1.19%	-0.18%	0.16%	0.3%	-0.33%	0.38%	-0.38%
FCF per Share	-40.19	-33.76	-24.11	-42.64	-46.25	-33.39	-22.50	-27.42	-12.18	-15.71
FCF Conversion (FCF/Net Income)	0.80x	0.77x	0.57x	0.89x	0.96x	0.82x	0.86x	0.90x	0.65x	1.67x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-58.34%	-60.77%	-88.43%	-114.13%	-171.36%	-391.29%	-	-	-	-
Return on Invested Capital (ROIC)	-91.04%	-65.76%	-113.15%	-118.2%	-133.02%	-182.33%	-2375.99%	-391.67%	-1229.11%	-
Gross Margin	-38997.6%	-56353.25%	-6583.68%	-431.95%	94.11%	97.5%	98.38%	96.68%	96.62%	95.86%
Net Margin	-47272.4%	-71153.9%	-8036.39%	-588.1%	-488.08%	-181.59%	-59.14%	-105.23%	-97.99%	-52.62%
Debt / Equity	-	-	-	0.56x	2.51x	2.59x	-	-	-	-
Interest Coverage	-	-	-	-72.16x	-12.10x	-6.33x	-3.77x	-5.69x	-5.44x	-3.19x
FCF Conversion	0.80x	0.77x	0.57x	0.89x	0.96x	0.82x	0.86x	0.90x	0.65x	1.67x
Revenue Growth	9.17%	-38.4%	942.21%	1790.09%	34.8%	164.31%	94.12%	-25.14%	-7.03%	-0.55%

Revenue by Segment

	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	15.67M	24.36M	28.01M
License and Service Growth	-	-	-	-	55.44%	15.00%
Health Care, Other	-	-	-	-	-	2.74M
Health Care, Other Growth	-	-	-	-	-	-
License	-	-	-	-	3.5M	-
License Growth	-	-	-	-	-	-
Royalty	-	-	-	300K	1.5M	-
Royalty Growth	-	-	-	-	400.00%	-
License And Other	10.35M	31.88M	111.38M	-	-	-
License And Other Growth	-	207.88%	249.44%	-	-	-
Product	30.54M	76.21M	98.44M	-	-	-
Product Growth	-	149.54%	29.16%	-	-	-

Revenue by Geography

	2019	2020	2021	2022	2023	2024
CANADA	-	5M	-	-	-	-
CANADA Growth	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Karyopharm Therapeutics Inc. (KPTI) reported $142.5M in revenue for fiscal year 2024. This represents a 93670% increase from $0.2M in 2011.

Karyopharm Therapeutics Inc. (KPTI) saw revenue decline by 0.5% over the past year.

Karyopharm Therapeutics Inc. (KPTI) reported a net loss of $124.6M for fiscal year 2024.

Dividend & Returns

Karyopharm Therapeutics Inc. (KPTI) had negative free cash flow of $83.4M in fiscal year 2024, likely due to heavy capital investments.